Emergent endoscopy is associated with lower mortality in hemodynamically unstable upper GI bleeding: Single-center experience with 24/7 endoscopy services.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
BACKGROUND AND AIMS: The effectiveness of emergent endoscopy (EE), defined as endoscopy performed within six hours of admission, for improving outcomes in patients presenting with acute upper gastrointestinal bleeding (AUGIB) remains controversial. This study aimed to evaluate the impact of EE on 42-day rebleeding and mortality rates and identify subgroups of patients who benefit most from this approach. METHODS: We conducted a retrospective cohort study at a tertiary hospital with 24/7 endoscopy services. Eligible patients were aged ≥18 years, presented with AUGIB, and underwent endoscopy within 24 h of admission. The exclusion criteria included prior interventions at other facilities, in-hospital bleeding for unrelated reasons, or loss to follow-up. All patients were managed under a standardized AUGIB protocol. The primary outcomes were 42-day rebleeding and mortality. The data were analysed via multivariate logistic regression and interaction analyses. RESULTS: There were 651 patients with a median age of 58.6 years (18-92). The median time from admission to endoscopy was 4.8 h (3.1-8.0). The 42-day rebleeding and mortality rates were 16.7 % and 11.8 %, respectively. EE was significantly associated with 42-day mortality but not rebleeding. Independent risk factors for mortality included hemodynamic instability, malignancy, NSAID use, and elevated serum creatinine. Interaction analysis revealed that EE was associated with reduced 42-day mortality in hemodynamically unstable patients (OR: 0.29, 95 % CI: 0.145-0.579), a benefit not observed in patients with other risk factors for mortality. CONCLUSION: EE appears to be associated with reduced 42-day mortality in patients presenting with hemodynamically unstable AUGIB.